Canadian CTA Frequently Asked Questions

Exploring new compounds in early-phase clinical research in Canada presents notable advantages over other regions. Adherence to International Conference on Harmonisation (ICH) guidelines ensures studies conducted in Canada uphold high-quality standards, regulatory compliance, and ethical norms. Such studies are frequently relied upon to support drug applications across global regulatory agencies.

This document aims to alleviate common concerns and questions for those contemplating a Clinical Trial Application (CTA) in Canada.